Erigeron breviscapus extraction dry suspensoid agent

A technology of breviscapine and dry suspension, which is applied in powder delivery, cardiovascular system diseases, organic active ingredients, etc., and can solve the problems of poor patient compliance, poor bioavailability, poor water solubility and fat solubility, etc. Achieve good redispersibility, slow settling rate and good fluidity

Inactive Publication Date: 2005-01-05
FUDAN UNIV
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Because breviscapine is a flavonoid component, its water solubility and fat solubility are very poor, so the common granules and tablets taken orally often have slow onset of action and poor bioavailability due to dissolution problems; although there are currently dispersible tablets, Oral immediate-release preparations such as dropping pills, but their pharmacokinetic characteristics and bioavailability in vivo have not been reported
Although breviscapine injection has fast absorption and high bioavailability, it is inconvenient to use, poor patient compliance, and inconvenient to prepare, pack, transport and store

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Erigeron breviscapus extraction dry suspensoid agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Breviscapine 20g

[0025] Microcrystalline Cellulose 200g

[0026] Povidone 20g

[0027] Micro Powder Silica 10g

[0028] Magnesium Stearate 10g

[0029] Flavor 10g

[0030] Lactose added to 1000g

[0031] According to the above components, take scutellarin and crush it and pass it through a 120-mesh sieve. Other auxiliary materials except the flavoring agent are dried and crushed through a 100-mesh sieve. The active ingredient scutellarin is mixed with microcrystalline cellulose, polymer Vidone and lactose are mixed evenly, and then micropowder silica gel, magnesium stearate and flavoring agent are added, and the mixture is fully mixed to form a solid powder, which is divided into single doses. A total of 1000 bags were made, each bag weighing 1g, which contained 20mg of breviscapine.

Embodiment 2

[0033] Breviscapine 20g

[0034] Microcrystalline Cellulose 50g

[0035] Hydroxyethylcellulose 100g

[0036] Micro Powder Silica 10g

[0037] Magnesium Stearate 10g

[0038] Mannitol added to 1000g

[0039] According to the above-mentioned components, take breviscapine and pulverize and pass through a 120-mesh sieve, and other auxiliary materials are respectively dried and pulverized and passed through a 100-mesh sieve. Mix the active ingredient breviscapine with microcrystalline cellulose, hydroxyethyl cellulose, and mannitol by an equal amount incremental method, then add micropowder silica gel and magnesium stearate, mix well, and divide into single doses. A total of 1000 bags are prepared, each bag is 1g, containing 20mg of breviscapine.

Embodiment 3

[0041] Breviscapine 40g

[0042] Hypromellose 100g

[0043] Sodium Carboxymethyl Cellulose 40g

[0044] Micronized talc 10g

[0045] Magnesium Stearate 10g

[0046] Flavor 10g

[0047] Mannitol added to 1000g

[0048] According to the above component amounts, take breviscapine and pulverize and pass through a 120-mesh sieve, and other auxiliary materials except the flavoring agent are respectively dried and pulverized and passed through a 100-mesh sieve. Mix the active ingredient breviscapine with hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and mannitol by an equal amount incremental method, and then add micronized talc, magnesium stearate and flavoring agent and mix well. Dispense in single doses. A total of 1000 bags are made, each bag is 1g, containing 40mg of breviscapine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A dried suspension for treating cardiovascular and cerebrovascular diseases is prepared from breviscapine, filler, suspending aid, flowing aid, lubricant and flavouring through drying, pulverizing and proportional mixing. It is mixed with water before used.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a pharmaceutical preparation for treating cardiovascular and cerebrovascular diseases. It specifically relates to a dry suspension containing breviscapine. Background technique [0002] Brevescapine (Brevescapine) is a class of flavonoids isolated from the Asteraceae plant (formerly known as Dengzhanhua, also known as Dengzhan Asarum, Erigeron Breviscapus (Vant.) Hand.-Mazz.), mainly containing Scutellarin (chemical name 4', 5, 6-trihydroxyflavonoid-7-glucuronide) also contains a small amount of scutellarin and other flavonoids. [0003] Existing pharmacodynamic studies have shown that breviscapine can dilate cerebral blood vessels, reduce cerebrovascular resistance, increase cerebral blood flow, improve microcirculation, improve blood-brain barrier permeability, enhance the phagocytic immune function of macrophages, and fight against the pituitary gland. Vasoline-induc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K31/7048A61P9/10
Inventor 翁伟宇黄建明徐惠南沈腾张建芳
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap